Home/ Author / Ishan Dan
    Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

  • All Categories

  • All Categories

  • TO BE RECATEGORIZED

  • Investing 101

  • Opinion

  • News

  • Leaders

  • Uncategorized

  • ASX

  • Crypto

  • Global

  • Economics

  • Investing

  • Markets

  • Broker picks

  • Asset allocation

  • Regulation

  • IPO

  • Growth

  • ESG

  • Alternatives

  • Advice

  • Property

  • Funds Management

Ishan Dan

Contributor

Ishan is an experienced journalist covering The Inside Investor and The Insider Adviser publications.

Ishan Dan results

Jeweller delivers dividend gold, hearing aids impacted by shutdown

Lovisa delivers a great result and reinstates dividend Lovisa Holdings (ASX: LOV) – Shares in the jewellery retailer surged 19% following a bumper profit result. While revenue was down 9.8% and comparable-store sales down 4.5% for the period, the company continued its store rollout with 29 new stores built. Gross profit decreased 11.7% to $113m…

Ishan Dan | 19th Feb 2021 | More
Growth darling underperforms, retailer delivers bumper dividend

Dividend boom JB Hi-Fi (ASX: JBH) has done it again. A bumper result saw shares increase 2.5% at the time of writing, on the back of strong in-store and online growth in the Australian electronics market. The electronics retailer posted a first-half profit inline with market expectations, and pointed towards an optimistic second half. Total…

Ishan Dan | 19th Feb 2021 | More
BNPL – Can Zip Co (ASX: Z1P) catch Afterpay (ASX: APT)?

Afterpay this, Afterpay that… what started five years ago as a small payments platform quickly became one of Australia’s most valuable and iconic companies. Afterpay listed at $1.00 only a few years ago (April 2016), and on today’s numbers is worth a staggering $41.7 billion at $150 a share. That is an astronomical gain of…

Ishan Dan | 19th Feb 2021 | More
Biotech BARD1 cancer detection treatment gaining traction

BARD1 Life Sciences (ASX: BD1) – Earlier in the week, the Inside Investor team published an article on BARD1 Life Sciences (click here) and its meteoric rise following a positive announcement on ovarian cancer detection. Shares have risen from 74.5c on the day of the announcement to $3.20 at the time of writing. That’s a…

Ishan Dan | 17th Feb 2021 | More
Nearmap (ASX: NEA) defends a short-selling attack

Last week, Beijing based short-selling activist firm J Capital launched a scathing report on Australian aerial imagery technology firm (and small cap darling) Nearmap (ASX: NEA), in the hope that it would trigger a sell-off so that it could profit handsomely from short positions in the company. The report titled “Afraid to Admit Failure” attacked…

Ishan Dan | 17th Feb 2021 | More
  • Dividends in focus at Telstra (ASX:TLS) and AMP (ASX:AMP)

    Telstra (ASX: TLS) – Shares closed the day +2.5 per cent on the back of a reasonable result and a series of amended growth targets. CEO Andy Penn delivered a result which was in line with guidance despite a fall in underlying earnings of 14.2 per cent to $3.3 billion. Similarly net profit fell 2.2…

    Ishan Dan | 14th Feb 2021 | More
    BetaShares to launch cloud computing ETF

    The effects of COVID-19 and the lockdowns that followed have changed the way we interact and conduct business forever. The virus had a big impact on almost every sector of the economy, forcing employees to work from home and businesses to accelerate the process of digitisation out of necessity rather than choice, in order to…

    Ishan Dan | 14th Feb 2021 | More
    Biotech share doubles on positive cancer announcement

    BARD1 Life Sciences (ASX: BD1) – The Melbourne-based biotech’s shares rocketed 132 per cent following a positive announcement last Thursday on ovarian cancer detection. The company said Griffith University’s Institute of Glycomics had released data showing that the company’s licensed SubB2M technology can be used to detect all stages of ovarian cancer with 100% specificity…

    Ishan Dan | 14th Feb 2021 | More
    ASX reporting season: CBA and Dexus

    CBA (ASX:CBA) Result comes in neat and tidy Cash profit for HY of $3.89 billion, versus the analysts’ consensus expectation of $3.76 billion Strong balance sheet with $10 billion in excess capital Higher dividend and capital strength CBA shares are down in early trade despite posting a “beat” on cash earnings. The bank posted a…

    Ishan Dan | 10th Feb 2021 | More
    Battleground – Robotics, Automation and AI

    With the onset of COVID-19 and the lockdowns that followed, the move to digital accelerated, becoming a shift of necessity rather than choice. The move occurred almost seamlessly. Bricks-and-mortar retailers shifted online, triggering a move to digital with buy-now, pay-later (BNPL) vendors popping up offering solutions to replace physical cash. This is just one example…

    Ishan Dan | 5th Feb 2021 | More
    1 42 43 44 45 46 52
    Our Authors
    Popular